Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Biocorp
  6. News
  7. Summary
    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biocorp : To Develop Add-On Device For Novo Nordisk's Insulin Pen

09/27/2021 | 02:19am EST


ę MT Newswires 2021
All news about BIOCORP
2021Sanofi Collaborates With Roche Unit for Medical Device for Insulin Pens
MT
2021GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
2021BIOCORP : To Develop Add-On Device For Novo Nordisk's Insulin Pen
MT
2021Biocorp Production Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021BIOCORP : Half-year results
CO
2021BIOCORP : Upcoming investor meetings
PU
2021GLOBAL MARKETS LIVE : Thales, Nestlé, Evergrande, AMC, Walmart...
2021BIOCORP : and MERCK KGaA sign a partnership in the field of Human Growth Hormone
PU
2021BIOCORP : and ROCHE DIABETES CARE FRANCE launch Mallya in France
PU
2021BIOCORP and Roche Diabetes Care France Announces the Launch in France of Mallya
CI
More news
Financials
Sales 2021 12,8 M 14,6 M 14,6 M
Net income 2021 -1,08 M -1,23 M -1,23 M
Net Debt 2021 7,45 M 8,50 M 8,50 M
P/E ratio 2021 -120x
Yield 2021 -
Capitalization 129 M 147 M 147 M
EV / Sales 2021 10,6x
EV / Sales 2022 6,99x
Nbr of Employees 67
Free-Float 53,9%
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 29,60 €
Average target price 31,40 €
Spread / Average Target 6,08%
EPS Revisions
Managers and Directors
Eric Dessertenne Chief Executive Officer
StÚphane Chabanais VP-Finance, Director-Finance & Administration
Jacques Gardette Chairman
Alain Marcoz Director-Research & Development
Jean-Yves Berthon Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOCORP2.07%147
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317